SC Adult & adolescent ≥13 yr 0.5 mL dose, then a 2nd 0.5 mL dose 4-8 wk later. Childn 12 mth to 12 yr 0.5 mL dose. If 2nd dose is administered, allow a min interval of 3 mth between doses.
History of anaphylactic or severe allergic reaction to any component of the vaccine (including neomycin & gelatin) or to a previous dose of a varicella-containing vaccine. Individuals who are immunodeficient or immunosuppressed due to disease or medical therapy. Active febrile illness w/ fever >101.3°F (>38.5°C). Active, untreated TB. Pregnancy. Women planning on becoming pregnant in the next 3 mth.
Defer vaccination in individuals w/ a family history of congenital or hereditary immunodeficiency until immunocompetence is confirmed. Use in HIV-infected individuals. Risk of vaccine virus transmission. Do not give concurrently w/ Ig & other blood products. Avoid use of salicylates (aspirin) or salicylate-containing products in childn & adolescents 12 mth to 17 yr for 6 wk following vaccination due to association of Reye syndrome w/ salicylate therapy & wild-type varicella infection. Lactation.
Concurrent administration w/ Ig & other blood products may interfere w/ expected immune response. May result in a temporary depression of tuberculin skin sensitivity. If a tuberculin skin test w/ tuberculin purified protein derivative (PPD) is to be done, administer before, on the same day, or at least 4 wk after vaccination w/ Varivax. Can be administered concurrently w/ other live viral vaccines. If not given concurrently, at least 1 mth should elapse between a dose of live attenuated measles virus-containing vaccine & a dose of Varivax. Can be concomitantly administered w/ MMR II, H. influenzae type b conjugate (meningococcal protein conjugate), hepatitis B (recombinant), inactivated diphtheria-tetanus & acellular pertussis vaccines.
Sign Out
